- Home
- SEAT vs ORIC Comparison
SEAT vs ORIC Comparison
Compare SEAT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- ORIC
- Stock Information
- Founded
- SEAT 2001
- ORIC 2014
- Country
- SEAT United States
- ORIC United States
- Employees
- SEAT N/A
- ORIC N/A
- Industry
- SEAT Industrial Machinery/Components
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- SEAT Industrials
- ORIC Health Care
- Exchange
- SEAT Nasdaq
- ORIC Nasdaq
- Market Cap
- SEAT 622.1M
- ORIC 735.3M
- IPO Year
- SEAT N/A
- ORIC 2020
- Fundamental
- Price
- SEAT $4.48
- ORIC $10.84
- Analyst Decision
- SEAT Strong Buy
- ORIC Strong Buy
- Analyst Count
- SEAT 10
- ORIC 9
- Target Price
- SEAT $6.73
- ORIC $18.75
- AVG Volume (30 Days)
- SEAT 1.1M
- ORIC 825.1K
- Earning Date
- SEAT 03-04-2025
- ORIC 03-10-2025
- Dividend Yield
- SEAT N/A
- ORIC N/A
- EPS Growth
- SEAT N/A
- ORIC N/A
- EPS
- SEAT N/A
- ORIC N/A
- Revenue
- SEAT $774,076,000.00
- ORIC N/A
- Revenue This Year
- SEAT $10.17
- ORIC N/A
- Revenue Next Year
- SEAT $4.02
- ORIC N/A
- P/E Ratio
- SEAT N/A
- ORIC N/A
- Revenue Growth
- SEAT 13.91
- ORIC N/A
- 52 Week Low
- SEAT $3.24
- ORIC $6.33
- 52 Week High
- SEAT $6.41
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- SEAT 49.56
- ORIC 52.90
- Support Level
- SEAT $4.13
- ORIC $9.92
- Resistance Level
- SEAT $4.78
- ORIC $12.00
- Average True Range (ATR)
- SEAT 0.26
- ORIC 0.90
- MACD
- SEAT -0.08
- ORIC 0.04
- Stochastic Oscillator
- SEAT 26.67
- ORIC 41.82
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.